In Vivo PK/PD Evaluation Service for Veterinary (Pet) Antibody

In vivo PK/PD evaluation for veterinary therapeutic antibody development. Bridging the gap from bench to clinic for your veterinary biologics. Are you currently facing challenges with unpredictable in vivo antibody behavior, complex dose-regimen selection for target pet species, or difficulty translating in vitro results into clinical efficacy? Creative Biolabs' in vivo PK/PD evaluation service helps you de-risk your development pipeline and optimize therapeutic candidates by establishing a clear dose-exposure-response relationship. This is achieved through our species-specific animal models and advanced bioanalytical and pharmacokinetic modeling platforms.

Introduction

Our service is designed to provide a comprehensive understanding of how your therapeutic antibody behaves within the target animal species. We deliver critical data that characterizes the pharmacokinetics (what the animal's body does to the antibody) and pharmacodynamics (what the antibody does to the animal's body). This integration is crucial for selecting the right candidates to move forward, defining optimal dosing strategies for future efficacy and safety studies, and building a robust data package for regulatory submissions. We translate complex biological interactions into clear, actionable insights for your project's success.

Discover How We Can Help - Request a Consultation

Workflow

Our in vivo PK/PD evaluation service provides species-specific pharmacokinetic and pharmacodynamic insights to guide dosing strategies, predict clinical outcomes, and de-risk therapeutic antibody development for companion animals.

Fig 1. Pet Antibody In Vivo PK/PD Evaluation Service Workflow. (Creative Biolabs Original)

Study Planning & Objective Setting	We work with you to define study goals, select target species, and determine the appropriate PK/PD parameters to be measured. Protocols are aligned with veterinary regulatory guidelines and tailored to your therapeutic mechanism.
Animal Model Development	We select or establish suitable animal models (healthy or disease-relevant) to accurately capture the in vivo exposure and biological activity of your antibody. Model selection considers species physiology, FcRn binding, and target expression.
Dosing & Administration	Antibody candidates are administered through clinically relevant routes (e.g., IV, SC, IM) at defined doses. We can conduct both single-dose and multiple-dose regimens to map the complete PK/PD profile.
Sample Collection & Bioanalysis	Blood and, where applicable, tissue samples are collected at scheduled intervals. We quantify antibody concentrations using validated ELISA, LC-MS/MS, or ligand-binding assays, and assess PD biomarkers such as target occupancy, cytokine modulation, or functional readouts.
Data Modeling & Interpretation	PK parameters (Cmax, Tmax, AUC, half-life, clearance) and PD responses are analyzed using industry-standard modeling tools to establish exposure–response relationships. This data supports dose optimization and clinical translation.
Final Reporting	A detailed technical report includes study methodology, raw and processed data, PK/PD curves, statistical analysis, and expert interpretation, ready for internal review or regulatory submission.

Why Choose Us?

Specialized Veterinary Expertise
Our team possesses deep experience in the physiology and immunology of canine and feline models. We understand the species-specific differences that are critical for accurate data interpretation and clinical translation.
Advanced Bioanalytical Platforms
We employ highly sensitive and validated ligand-binding assay platforms to ensure the accuracy and reproducibility of your PK and PD data. We can also develop and validate custom assays tailored specifically to your antibody and its target.
Integrated PK/PD Modeling
We go beyond simple data generation. Our experts use sophisticated modeling to connect drug exposure with biological effect, providing powerful insights for dose prediction and optimizing the therapeutic window.

Fig 2. Evaluation of the caninized cPD-L1 chimeric antibody. ^1,2

FAQs

1. How do you measure the pharmacodynamic (PD) effects of our antibody?

PD effects are measured using biomarkers that reflect the antibody's biological activity. This can range from measuring the levels of a soluble target (e.g., a cytokine), assessing changes in a specific cell population via flow cytometry, or analyzing the expression of a downstream gene. The best approach depends on your antibody's mechanism of action, and we work with you to select or develop the most relevant assays.

2. Can you help if we haven't fully developed our bioanalytical assays yet?

Absolutely. Our team has extensive experience in developing, optimizing, and validating custom ligand-binding assays (e.g., ELISA) for quantifying therapeutic antibodies and biomarkers in various biological matrices. Our assay development service can be seamlessly integrated into your PK/PD study plan.

Related Services

To fully support your veterinary therapeutic development pipeline, Creative Biolabs also offers a suite of complementary in vivo services.

In Vivo Efficacy Evaluation

Test your antibody's therapeutic effect in established or custom disease models for companion animals.

In Vivo Safety Evaluation

Conduct preliminary safety and tolerability studies to identify potential safety liabilities early.

Animal Model Customization

We can collaborate with you to develop and characterize novel animal models tailored to your specific therapeutic area or mechanism of action.

Partner with Creative Biolabs

Creative Biolabs provides the critical in vivo PK/PD data and expert interpretation you need to make confident decisions and accelerate your veterinary antibody program. Our dedication to scientific excellence, specialized veterinary models, and collaborative partnership ensures your project is positioned for success.

Our team of scientific experts is ready to discuss your unique project needs and how our services can help you achieve your development goals. Reach out today for a no-obligation consultation and to receive a detailed proposal. Contact our team to learn more about our customized solutions for your pet therapeutic antibody in vivo PK/PD evaluation project.

Contact Our Team for More Information and to Discuss Your Project.

References

Oh, Wonkyung et al. "Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans." Cancer research communications vol. 3,5 860-873. 15 May. 2023, https://doi.org/10.1158/2767-9764.CRC-22-0468
Distributed under Open Access license CC BY 4.0, without modification.

Services